|Benefit-Cost Summary Statistics Per Participant|
|Taxpayers||$3,200||Benefits minus costs||$22,450|
|Participants||$4,125||Benefit to cost ratio||$38.29|
|Others||$1,591||Chance the program will produce|
|Indirect||$14,136||benefits greater than the costs||76%|
|Net program cost||($602)|
|Benefits minus cost||$22,450|
|Meta-Analysis of Program Effects|
|Outcomes measured||Treatment age||No. of effect sizes||Treatment N||Adjusted effect sizes(ES) and standard errors(SE) used in the benefit - cost analysis||Unadjusted effect size (random effects model)|
|First time ES is estimated||Second time ES is estimated|
Alcohol use disorder^^
Clinical diagnosis of alcohol use disorder or symptoms measured on a validated scale.
Illicit drug use disorder
Clinical diagnosis of illicit drug use disorder or symptoms measured on a validated scale. When possible, we exclude cannabis/marijuana use disorder from this outcome.
Adult use of cannabis that does not rise to the level of “disordered.”
|Detailed Monetary Benefit Estimates Per Participant|
|Affected outcome:||Resulting benefits:1||Benefits accrue to:|
|Illicit drug use disorder||Criminal justice system||$2||$0||$4||$1||$6|
|Labor market earnings associated with illicit drug abuse or dependence||$1,195||$2,807||$0||($597)||$3,404|
|Health care associated with illicit drug abuse or dependence||$1,544||$239||$1,587||$772||$4,142|
|Mortality associated with illicit drugs||$459||$1,079||$0||$14,262||$15,800|
|Program cost||Adjustment for deadweight cost of program||$0||$0||$0||($301)||($301)|
|Detailed Annual Cost Estimates Per Participant|
|Annual cost||Year dollars||Summary|
|Program costs||$548||2012||Present value of net program costs (in 2018 dollars)||($602)|
|Comparison costs||$0||2012||Cost range (+ or -)||20%|
Benefits Minus Costs
Benefits by Perspective
Taxpayer Benefits by Source of Value
|Benefits Minus Costs Over Time (Cumulative Discounted Dollars)|
|The graph above illustrates the estimated cumulative net benefits per-participant for the first fifty years beyond the initial investment in the program. We present these cash flows in discounted dollars. If the dollars are negative (bars below $0 line), the cumulative benefits do not outweigh the cost of the program up to that point in time. The program breaks even when the dollars reach $0. At this point, the total benefits to participants, taxpayers, and others, are equal to the cost of the program. If the dollars are above $0, the benefits of the program exceed the initial investment.|
Alessi, S.M., Hanson, T., Wieners, M., & Petry, N.M. (2007). Low-cost contingency management in community clinics: delivering incentives partially in group therapy. Experimental and Clinical Psychopharmacology, 15(3), 293-300.
Brooner, R.K., Kidorf, M.S., King, V.L., Stoller, K.B., Neufeld, K.J., & Kolodner, K. (2007). Comparing adaptive stepped care and monetary-based voucher interventions for opioid dependence. Drug and Alcohol Dependence, 88, S14-S23.
Carroll, K.M., Ball, S.A., Nich, C., O'Connor, P.G., Eagan, D.A., Frankforter, T.L., Triffleman, E.G., Shi, J., & Rounsaville, B.J. (2001). Targeting behavioral therapies to enhance naltrexone treatment of opioid dependence: efficacy of contingency management and significant other involvement. Archives of General Psychiatry, 58(8), 755-761.
Carroll, K.M., Sinha, R., Nich, C., Babuscio, T., & Rounsaville, B.J. (2002). Contingency management to enhance naltrexone treatment of opioid dependence: a randomized clinical trial of reinforcement magnitude. Experimental and Clinical Psychopharmacology, 10(1), 54-63.
Chutuape, M.A., Silverman, K., & Stitzer, M. (1999). Contingent reinforcement sustains post-detoxification abstinence from multiple drugs: A preliminary study with methadone patients. Drug and Alcohol Dependence, 54(1), 69-81.
Downey, K.K., Helmus, T.C., & Schuster, C.R. (2000). Treatment of heroin-dependent poly-drug abusers with contingency management and buprenorphine maintenance. Experimental and Clinical Psychopharmacology, 8(2), 176-184.
Elk, R., Mangus, L., Rhoades, H., Andres, R., & Grabowski, J. (1998). Cessation of cocaine use during pregnancy: effects of contingency management interventions on maintaining abstinence and complying with prenatal care. Addictive Behaviors, 23(1), 57-64.
Epstein, D.H., Hawkins, W.E., Covi, L., Umbricht, A., & Preston, K.L. (2003). Cognitive-behavioral therapy plus contingency management for cocaine use: Findings during treatment and across 12-month follow-up. Psychology of Addictive Behaviors, 17(1), 73-82.
Epstein, D.H., Schmittner, J., Umbricht, A., Schroeder, J.R., Moolchan, E.T., & Preston, K.L. (2009). Promoting abstinence from cocaine and heroin with a methadone dose increase and a novel contingency. Drug and Alcohol Dependence, 101(1), 92-100.
Garcia-Fernandez, G., Secades-Villa, R., Garcia-Rodriguez, O., Sanchez-Hervas, E., Fernandez-Hermida, J.R., & Higgins, S.T. (2011). Adding voucher-based incentives to community reinforcement approach improves outcomes during treatment for cocaine dependence. The American Journal on Addictions, 20(5), 456-461.
Hall, S.M., Bass, A., Hargreaves, W.A., & Loeb, P. (1979). Contingency management and information feedback in outpatient heroin detoxification. Behavior Therapy, 10(4), 443-451.
Higgins, S.T., Budney, A.J., Bickel, W.K., Foerg, F.E., Donham, R., & Badger, G.J. (1994). Incentives Improve Outcome in Outpatient Behavioral Treatment of Cocaine Dependence. Archives of General Psychiatry 51(7), 568-576.
Higgins, S.T., Wong, C.J., Badger, G.J., Odgen, D.E.H., Dantona, R.L. (2000). Contingent Reinforcement increases cocaine abstinence during outpatient treatment and 1 year of follow-up. Journal of Consulting and Clinical Psychology, 68(1), 64-72.
Jones, H.E., Haug, N., Silverman, K., Stitzer, M., & Svikis, D. (2001). The effectiveness of incentives in enhancing treatment attendance and drug abstinence in methadone-maintained pregnant women. Drug and Alcohol Dependence, 61(3), 297-306.
Kennedy, A.P., Phillips, K.A., Epstein, D.H., Reamer, D.A., Schmittner, J., & Preston, K.L. (2013). A randomized investigation of methadone doses at or over 100mg/day, combined with contingency management. Drug and Alcohol Dependence, 130(1), 77-84.
Kirby, K.C., Marlowe, D.B., Festinger, D.S., Lamb, R.J., & Platt, J.J. (1998). Schedule of voucher delivery influences initiation of cocaine abstinence. Journal of Consulting and Clinical Psychology, 66(5), 761-7.
Kosten, T., Oliveto, A., Feingold, A., Poling, J., Sevarino, K., McCance-Katz, E., Stine, S., ... Gonsai, K. (2003). Desipramine and contingency management for cocaine and opiate dependence in buprenorphine maintained patients. Drug and Alcohol Dependence, 70(3), 315-325.
Oliveto, A., Poling, J., Sevarino, K.A., Gonsai, K.R., McCance-Katz, E.F., Stine, S.M., & Kosten, T.R. (2005). Efficacy of dose and contingency management procedures in LAAM-maintained cocaine-dependent patients. Drug and Alcohol Dependence, 79(2), 157-165.
Petry, N.M. and B. Martin. (2002). Low-Cost Contingency Management for Treating Cocaine- and Opioid-Abusing Methadone Patients. Journal of Consulting and Clinical Psychology, 70(2), 398-405
Petry, N.M., Martin, B., & Simcic, F. (2005). Prize Reinforcement Contingency Management for Cocaine Dependence: Integration with Group Therapy in a Methadone Clinic. Journal of Consulting and Clinical Psychology, 73(2), 354-359.
Petry, N.M., Alessi, S.M., Marx, J., Austing, M., Tardif, M. 2005. Vouchers versus prizes: Contingency management treatment of substance abusers in community settings. Journal of Consulting and Clinical Psychology, 73(6), 1005-1014
Petry, N.M., Alessi, S.M., Carroll, K.M., Hanson, T., MacKinnon, S., Rounsaville, B., & Sierra, S. (2006). Contingency Management Treatments: Reinforcing Abstinence Versus Adherence with Goal-Related Activities. Journal of Consulting and Clinical Psychology, 74(3), 592-601.
Piotrowski, N.A., Tusel, D.J., Sees, K.L., Reilly, P.M., Banys, P., Meek, P., et al. (1999). Contingency contracting with monetary reinforcers for abstinence from multiple drugs in a methadone program. Experimental and Clinical Psychopharmacology, 7(4), 399-411.
Preston, K.L., Umbricht, A., & Epstein, D.H. (2000). Methadone dose increase and abstinence reinforcement for treatment of continued heroin use during methadone maintenance. Archives of General Psychiatry, 57(4), 395-404.
Rawson, R.A., Huber, A., McCann, M., Shoptaw, S., Farabee, D., Reiber, C., & Ling, W. (2002). A comparison of contingency management and cognitive-behavioral approaches during methadone maintenance treatment for cocaine dependence. Archives of General Psychiatry, 59(9), 817-824.
Shoptaw, S., Reback, C.J., Peck, J.A., Yang, X., Rotheram-Fuller, E., Larkins, S., Veniegas, R.C., ... Hucks-Ortiz, C. (2005). Behavioral treatment approaches for methamphetamine dependence and HIV-related sexual risk behaviors among urban gay and bisexual men. Drug and Alcohol Dependence, 78(2), 125-134.
Shoptaw, S., Huber, A., Peck, J., Yang, X., Liu, J., Jeff, D., Roll, J., ... Ling, W. (2006). Randomized, placebo-controlled trial of sertraline and contingency management for the treatment of methamphetamine dependence. Drug and Alcohol Dependence, 85(1), 12-18.
Silverman, K., Higgins, S.T., Brooner, R.K., Montoya, I.D., Cone, E.J. & Schuster, C.R. (1996). Sustained Cocaine Abstinence in Methadone Maintenance Patients Through Voucher-Based Reinforcement Therapy. Archives of General Psychiatry, 53(5), 409-415.
Silverman, K., Wong, C.J., Umbricht-Schneiter, A., Montoya, I.D., Schuster, C.R. & Preston, K.L. (1998). Broad Beneficial Effects of Cocaine Abstinence Reinforcement Among Methadone Patients. Journal of Consulting and Clinical Psychology, 66(5), 811-824.
Silverman, K., Robles, E., Mudric, T., Bigelow, G.E., & Stitzer, M.L. (2004). A Randomized Trial of Long-Term Reinforcement of Cocaine Abstinence in Methadone-Maintained Patients Who Inject Drugs. Journal of Consulting and Clinical Psychology, 72(5), 839-854.